ImmGenics Pharmaceuticals

Vancouver, Canada Founded: 1993 • Age: 33 yrs Acquired By Abgenix
Technology for antibody drug discovery.
Annual revenue - Latest available
Total funding - 1 rounds
Employees - Tracked headcount
Investors 2 Known backers
Products - Services tracked
Competitors 11 Brand Intelligence

About ImmGenics Pharmaceuticals

ImmGenics Pharmaceuticals is a company based in Vancouver (Canada) founded in 1993 was acquired by Abgenix in September 2000. ImmGenics Pharmaceuticals operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.

  • Headquarter Vancouver, Canada
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    $6 M (USD), Post-IPO

    May 16, 2000

  • Investors
    Nomura

    & 1 more

  • Employee Count
    Not available
  • Acquired by
    Abgenix

    (Sep 26, 2000)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of ImmGenics Pharmaceuticals

Investors in ImmGenics Pharmaceuticals

ImmGenics Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Nomura and Abgenix.

All
Institutional
Investor Description Founded Year Domain Location
Diversified asset management services are offered globally by the firm.
Locked Locked Locked
Fully human therapeutic antibodies for cancer and inflammation are discovered.
Locked Locked Locked
Premium access

Investor details for ImmGenics Pharmaceuticals

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by ImmGenics Pharmaceuticals

Investments
Premium access

Investment portfolio details for ImmGenics Pharmaceuticals

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - ImmGenics Pharmaceuticals

Premium access

Detailed financials for ImmGenics Pharmaceuticals

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Immgenics Pharmaceuticals Comparisons

ImmGenics Pharmaceuticals Primary company
Description
Technology for antibody drug discovery.
Location
Vancouver, Canada
Founded Year
1993
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for ImmGenics Pharmaceuticals

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of ImmGenics Pharmaceuticals

ImmGenics Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Developer of pharmaceuticals and vaccines for various therapeutic areas
Locked Locked Locked
Antibody-siRNA complexes are developed for cancer treatment.
Locked Locked Locked
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
Locked Locked Locked
Yeast cells are genetically engineered to produce medicinal products.
Locked Locked Locked
Developing novel drugs based on a proteome-wide ligand and target discovery platform
Locked Locked Locked
CRISPR-engineered cell and gene therapies are developed for research applications.
Premium access

Detailed competitors of ImmGenics Pharmaceuticals

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Immgenics Pharmaceuticals

Premium access

Complete news archive for ImmGenics Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ImmGenics Pharmaceuticals

ImmGenics Pharmaceuticals was founded in 1993 and raised its 1st funding round 7 years after it was founded.

ImmGenics Pharmaceuticals is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.

ImmGenics Pharmaceuticals was founded in 1993 in Vancouver, Canada, within the biotechnology sector. A proprietary lymphocyte antibody technology was created, by which B-cells are cultured directly and assayed over several days via a microplate-based throughput system. Greater numbers of antibodies can be screened for specific antigen targets as a result. Operations centered on advancing drug discovery processes until acquisition by Abgenix in November 2000.

ImmGenics Pharmaceuticals's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

ImmGenics Pharmaceuticals has 2 investors. Key investors include Nomura, and Abgenix.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available